0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
The Cutting Edge: Challenges in Medical and Surgical Therapies |

Treatment of Severe Cutaneous Small-Vessel Vasculitis With Mycophenolate Mofetil

M. Tye Haeberle, MD; William B. Adams, MD; Jeffrey P. Callen, MD
Arch Dermatol. 2012;148(8):887-888. doi:10.1001/archdermatol.2011.3037.
Text Size: A A A
Published online

Extract

Antineutrophilic cytoplasmic antibody (ANCA)-negative, cutaneous, small-vessel vasculitis (CSVV) is a well-described disease with a variety of treatment options. Mycophenolate mofetil (MMF) is an often-used immunosuppressive drug for inflammatory ailments. Herein we describe the first case of ANCA-negative CSVV treated successfully with MMF.

Correspondence: Dr Adams, Division of Dermatology, Department of Medicine, University of Louisville, 310 E Broadway, Ste 2A, Louisville, KY 40202 (will.adams@louisville.edu).

Accepted for Publication: December 1, 2011.

Author Contributions: All authors had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Haeberle, Adams, and Callen. Acquisition of data: Haeberle, Adams, and Callen. Analysis and interpretation of data: Haeberle, Adams, and Callen. Drafting of the manuscript: Haeberle. Critical revision of the manuscript for important intellectual content: Haeberle, Adams, and Callen. Administrative, technical, and material support: Adams and Callen. Study supervision: Adams and Callen.

Financial Disclosure: Dr Callen has received an honorarium for consulting for Glaxo Smith Kline and serves on a safety monitoring committee for Celgene.

Disclaimer: Dr Callen is the associate editor of the Archives of Dermatology. He was not involved in the editorial evaluation or decision to accept this article for publication.

Figures in this Article

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

First Page Preview

View Large
First page PDF preview

Figures

Place holder to copy figure label and caption
Graphic Jump Location

Figure 1. Purpuric, ulcerated lesions of anterior lower legs.

Place holder to copy figure label and caption
Graphic Jump Location

Figure 2. Resolution of lesions following 5 months of mycophenolate mofetil therapy.

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Jobs
brightcove.createExperiences();